ECP

ECP Pharma is a clinical-stage pharmaceutical company headquartered in Miami, Florida, specializing in the development of precision medicines for neurological and central nervous system (CNS) disorders. Founded in 2019, the company focuses on indications with significant unmet needs, such as mild traumatic brain injury (mTBI), amnestic mild cognitive impairment (aMCI), and multiple sclerosis (MS). Its therapeutic approach involves the use of underutilized active pharmaceutical ingredients (APIs), including combinations of cannabinoids and psychedelics. ECP Pharma collaborates with the University of Miami’s Miller School of Medicine to advance its research and clinical programs. The company aims to provide safe and effective therapies for conditions that currently lack clinically proven treatment options.